| | Webinar: Finding the right patients for clinical trials Tuesday, October 5 | 11am ET / 8am PT CROs that embrace these technologies could greatly improve the speed and efficiency of their trials. This webinar will explore the landscape of technologies and services that match patients to clinical trials, providing feedback from CRO executives who have experience with them. Register Now. |
Mass General Brigham vetoes controversial Alzheimer's drug Aduhelm after internal review What's next for RADx? The NIH drafts a to-do list for its $1.5B diagnostics competition, through COVID and beyond Despite rough start, Biogen's Aduhelm should find footing, analysts say. But don't expect much in 2021 Mirum gets iBAT inhibitor Livmarli across the FDA finish line for rare pediatric liver condition How exploiting a protective gene mutation might protect the brain from Alzheimer's disease Health systems-backed Truveta lands investment from Microsoft, cloud partnership Biotech incubator Sporos' new CEO arrives from Ovid with Biogen, Bristol Myers experience FDA alerts HCPs to higher risk for women with stroke-preventing heart implant AMA: 73% of health insurance markets are highly concentrated Featured Story | By Dave Muoio The Massachusetts system's decision not to provide Biogen's Aduhelm to patients follows a review by its internal expert panel. It comes after other big-name providers and payers said they would not support the treatment earlier this summer. read more |
| |
|---|
|
Top Stories By Andrea Park During a panel discussion about the initiative at AdvaMed’s annual MedTech Conference, the NIH's Bruce Tromberg outlined what’s next for RADx, which was launched as a “Shark Tank”-like competition to develop COVID tests as quickly as possible. read more By Eric Sagonowsky As Biogen's new Alzheimer's drug Aduhelm makes headlines nearly every day—many covering the drug's slower-than-expected uptake—one team of biopharma analysts is lowering their 2021 expectations for the med. Nonetheless, despite the drug sputtering out the gate, the team still sees a multibillion-dollar sales opportunity for the company in Alzheimer's disease. read more By Kevin Dunleavy Mirum Pharmaceuticals of California has taken Livmarli, a minimally absorbed ileal bile acid transporter (iBAT) inhibitor, across the FDA finish line. The drug =m which is taken in capsule form, is the first medication approved for the cholestatic pruritus which which accompanies the rare liver disorder Alagille syndrome. read more By Angus Liu A mutation in the APOE3 gene increases the formation of fatty molecules that are critical for preserving nerve cell functioning and that may reduce the toxic aggregation of protein clumps in the brain, a Mayo Clinic team has found. Targeting this process with drugs could protect against Alzheimer's disease, they suggested. read more By Heather Landi Healthcare data startup Truveta inked a deal with Microsoft to build a clinical data platform on the cloud. The software giant also is investing an undisclosed amount in Truveta, which is backed by 17 healthcare systems, including Providence, Novant Health, Northwell Health and Trinity Health. read more By Kyle LaHucik Amit Rakhit, M.D., is ready for his next venture after leaving Ovid Therapeutics last month following a lead therapy failure in April. His next stop is leading Houston biotech incubator Sporos Bioventures. read more By Conor Hale The agency alerted providers about findings published in JAMA Cardiology, which tracked procedures with Boston Scientific’s Watchman device. read more By Paige Minemyer Nearly three-quarters of metropolitan statistical areas are concentrated health insurance markets, according to a new study from the American Medical Association. read more |
